IMMX — Immix Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1873835 ·
Last close
$8.32
Market Cap
$592.30M
52W High
$12.14
52W Low
$7.65
ADV30
2,190,667
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,803,855 | -10,086,687 | 95,816,057 | 79,250,163 | 11,452,001 |
| Dec 2025 | 0 | — | -10,893,276 | -10,687,830 | 104,840,341 | 93,928,566 | 11,044,171 |
| Sep 2025 | 0 | — | -7,662,509 | -7,585,692 | 20,080,604 | 15,947,308 | 11,815,634 |
| Jun 2025 | 0 | — | -6,717,705 | -6,622,563 | 15,635,104 | 11,637,945 | 10,982,073 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,930,304
Investing CF
$-7,213,785
Financing CF
$107,386,859
CapEx
$-732,925
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.85
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-104,463,284
Inventory
—
Receivables
$0
ST Investments
$6,480,860
EBIT TTM
$-29,956,415
Pretax Income TTM
$-29,400,889
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,956,415 | -29,438,613 | 104,840,341 | 11,044,171 | — | -23,930,304 |
| Dec 2024 | 0 | -22,674,680 | -21,613,376 | 22,947,872 | 9,696,669 | — | -14,595,102 |
| Dec 2023 | 0 | -16,141,113 | -15,426,048 | 19,925,160 | 3,721,783 | — | -11,371,438 |
| Dec 2022 | 0 | -8,218,948 | -8,229,713 | 14,908,101 | 1,748,296 | — | -7,408,303 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.84
Max Pain — expiry 2026-08-21
max pain strike: $10.00 · spot: $8.32 · call oi: 1,581 · put oi: 2,593
Expected Move to 2026-08-21:
±$1.95
(23.44%) —
implied range
$6.37 –
$10.27
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRMD | CorMedix Inc. | $590.74M | $7.53 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $562.18M | $9.51 | — |
| RLMD | RELMADA THERAPEUTICS, INC. | $557.48M | $5.31 | — |
| MPLT | MapLight Therapeutics, Inc. | $554.89M | $13.02 | — |
| ALT | Altimmune, Inc. | $552.31M | $2.84 | — |
News headlines (Yahoo Finance, 1h cache)
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
2026-07-21 21:17 · Yahoo
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
2026-06-18 13:55 · Yahoo
Exploring 3 High Growth Tech Stocks in the US Market
2026-06-09 11:38 · Yahoo
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
2026-05-27 13:55 · Yahoo
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
2026-05-22 21:15 · Yahoo
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
2026-05-21 10:30 · Yahoo
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
2026-05-21 10:00 · Yahoo
3 Growth Companies With High Insider Ownership Expect Earnings Growth Up To 63%
2026-05-13 11:35 · Yahoo
Is Immix Biopharma (IMMX) One of the Best Performing NASDAQ Stocks?
2026-05-05 17:05 · Yahoo
We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth
2026-05-05 12:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.